Aclaris Therapeutics
ACRS
ACRS
148 hedge funds and large institutions have $579M invested in Aclaris Therapeutics in 2023 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 43 increasing their positions, 40 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
more ownership
Funds ownership: →
8% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 40
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
44% less capital invested
Capital invested by funds: $1.04B → $579M (-$456M)
Holders
148
Holding in Top 10
4
Calls
$26.5M
Puts
$20M
Top Buyers
| 1 | +$27.5M | |
| 2 | +$16.4M | |
| 3 | +$15.3M | |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$13.8M |
| 5 |
SC
Samlyn Capital
New York
|
+$8.51M |
Top Sellers
| 1 | -$43.4M | |
| 2 | -$28.5M | |
| 3 | -$10.1M | |
| 4 |
PA
Perceptive Advisors
New York
|
-$5.37M |
| 5 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$4.98M |